文章：

非小细胞肺癌中的Hippo信号通路：机制、潜在靶点及生物标志物

Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers

原文发布日期：2024-03-18 

英文摘要：

Lung cancer is the primary contributor to cancer-related deaths globally, and non-small cell lung cancer (NSCLC) constitutes around 85% of all lung cancer cases. Recently, the emergence of targeted therapy and immunotherapy revolutionized the treatment of NSCLC and greatly improved patients’ survival. However, drug resistance is inevitable, and extensive research has demonstrated that the Hippo pathway plays a crucial role in the development of drug resistance in NSCLC. The Hippo pathway is a highly conserved signaling pathway that is essential for various biological processes, including organ development, maintenance of epithelial balance, tissue regeneration, wound healing, and immune regulation. This pathway exerts its effects through two key transcription factors, namely Yes-associated protein (YAP) and transcriptional co-activator PDZ-binding motif (TAZ). They regulate gene expression by interacting with the transcriptional-enhanced associate domain (TEAD) family. In recent years, this pathway has been extensively studied in NSCLC. The review summarizes a comprehensive overview of the involvement of this pathway in NSCLC, and discusses the mechanisms of drug resistance, potential targets, and biomarkers associated with this pathway in NSCLC. 

摘要翻译： 

肺癌是全球癌症相关死亡的主要原因，其中非小细胞肺癌（NSCLC）约占所有肺癌病例的85%。近年来，靶向治疗和免疫疗法的出现彻底改变了NSCLC的治疗格局，显著提高了患者生存率。然而，药物耐药性不可避免，大量研究表明Hippo信号通路在NSCLC耐药机制中起关键作用。Hippo通路是一种高度保守的信号转导途径，在器官发育、上皮稳态维持、组织再生、伤口愈合及免疫调节等生物学过程中至关重要。该通路主要通过两个关键转录因子——Yes关联蛋白（YAP）和PDZ结合基序转录共激活因子（TAZ）发挥作用，它们通过与转录增强关联结构域（TEAD）家族相互作用来调控基因表达。近年来该通路在NSCLC领域受到广泛研究。本综述全面阐述了该通路在NSCLC中的参与机制，并深入探讨了其介导的耐药机制、潜在靶点及相关生物标志物。

原文链接：

Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers